Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Success stories

Mario Amendola – 2016 research chair


Mario Amendola directs the Genome Editing research group within Integrare
M. Amendola` M. Amendola`

With research chair funding from Genopole and MSD France, Mario Amendola was able to launch his innovative research on targeted genome interventions to correct the mutations responsible for a range of currently untreatable genetic blood disorders, including sickle-cell anemia, hemophilia, and beta thalassemia among others.

He created and directs today the Genome Editing research group within Integrare.
His work resulted in an ex vivo blood stem cell modification strategy involving Crispr-Cas9, the “genetic scissors” technology recognized by the 2020 Nobel Prize in Chemistry.

Mario Amendola’s strategy is aimed at harnessing hematopoietic stem cells for the production and blood-borne delivery of therapeutic proteins able to correct diseased cells.

CitationWith the Action Initiative Grants, I was able to create my own research team. My objective is to develop innovative approaches for targeted genome modifications—insertions, deletions, DNA repair—with the goal of definitively curing certain blood diseases (sickle-cell anemia, beta thalassemia, etc.) that currently have few therapeutic options. Thanks to this financing, our research on these promising tools is underway.” Mario Amendola

With support